Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CETP Inhibitors Back In The Fold: Amgen Dives In With Dezima Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

TA-8995 is potentially best-in-class and could fill a void in Amgen's portfolio for an oral agent, Exec VP R&D Sean Harper says in an interview. Development will focus on LDL-C lowering, not HDL-C increases.

You may also be interested in...



Start-Up Quarterly Statistics, Q3 2015

Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.

PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data

With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.

IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?

Sponsors of injectable PCSK9 biologics address questions about the implications of the IMPROVE-IT study, in which the soon-to-be-generic oral Zetia helped bring down LDL cholesterol to a very low level.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel